Acadia's Q3 Earnings Beat, Nuplazid & Daybue Drive Revenue Growth

Acadia Pharmaceuticals (ACAD) reported third-quarter 2024 earnings of 20 cents per share, beating the Zacks Consensus Estimate of 13 cents. In the year-ago quarter, the company had incurred a loss of 40 cents per share. Acadia recorded total revenues of $250 million, which beat the Zacks Consensus Estimate of $249 million. ACAD's net product revenues comprise revenues generated from the sale of its two marketed products, Nuplazid (pimavanserin) and the newly launched Daybue (trofinetide). ACAD's first drug, ...